MedPageToday The FDA granted emergency use authorization (EUA) for an updated Novavax COVID-19 vaccine to protect against hospitalization and death from circulating variants.
The protein-based shot represents a non-mRNA option for the 2024-2025 season, and follows the agency’s recent approvals and authorizations of the updated Moderna (Spikevax) and Pfizer-BioNTech (Comirnaty) vaccines
“The COVID-19 vaccines have had a tremendous positive impact on public health and vaccination continues to be the most effective method for COVID-19 prevention,” said Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research in the announcement.